Ambien CR

Quick links to important sections

Ambien CR

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ambien CR

Property Description
Active ingredient Zolpidem tartrate
Form Extended-release oral tablet (Dual-layer)
Pharmacological class Sedative-hypnotic agent, Non-benzodiazepine
Common use Insomnia (Sleep initiation and maintenance)
Origin Synthetic (Imidazopyridine derivative)

Ambien CR is the extended-release formulation of the synthetic compound Zolpidem tartrate, categorized as a sedative-hypnotic agent. This substance, primarily intended for adult patients, is a prescription-only medication (Rx). Chemically, it is classified as a non-benzodiazepine imidazopyridine derivative. The compound functions as a GABA receptor modulator, enhancing inhibitory effects in the central nervous system. The compound helps induce sleep by enhancing the natural calming effects of a chemical signal in the brain, a mechanism recognized for its high degree of selectivity compared to older classes of hypnotics.

This medication is an oral administration tablet designed with a specialized dual-layer architecture, which achieves a precise controlled release of the active ingredient. This unique dual-layer tablet architecture is clinically recognized for facilitating a biphasic release profile, distinguishing its design from immediate-release formulations of Zolpidem. The biphasic release profile is specifically indicated for the management of both difficulties with sleep onset and sleep maintenance. This dual-layered design ensures the medication assists both in quickly falling asleep and staying asleep throughout the night. The general purpose of the Zolpidem extended-release compound is to provide foundational support for adult patients managing difficulties associated with a sleep disorder or insomnia, aiming for a more complete period of rest.

Regulatory References

  1. NCBI Bookshelf

What side effects are possible with Ambien CR?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse effects of zolpidem tartrate extended-release by frequency and the body system affected. These classifications establish the medicine's official safety profile, detailing documented effects but offering no clinical advice or interpretation.


Frequency and System Classification

Adverse reactions are formally grouped into System-Organ Classes (SOC), including Nervous System Disorders and Psychiatric Disorders. Officially classified Common side effects—occurring in at least 1 in 100 patients—include headache, somnolence (next-day drowsiness), dizziness, diarrhea, and nausea. Uncommon reactions may include confusion, aggression, and somnambulism (sleepwalking), while Rare effects include gait disturbance and falls.


Serious Adverse Reactions and Safety Constraints

The prescribing information highlights the risk of serious adverse reactions, most notably complex sleep behaviors (e.g., sleep-driving or sleepwalking), which can lead to serious injury and are subject to a prominent regulatory warning. Other serious risks include life-threatening anaphylaxis and angioedema.

The drug's safety profile also includes specific constraints: Severe hepatic impairment is listed as a contraindication. Furthermore, the risk of impaired cognitive and motor performance, along with the risk of falls, is officially noted to be increased in older adults. The potential for next-day residual effects is a specific concern with the extended-release formulation, and rebound insomnia may occur upon abrupt discontinuation.

Overdose and Emergency Response

An overdose of zolpidem tartrate extended-release primarily presents with manifestations of Central Nervous System (CNS) depression. Documented symptoms may range from severe somnolence and impaired consciousness to a state of coma.

The official regulatory profiles emphasize that the severity of overdose effects is significantly increased when the drug is co-ingested with alcohol or other CNS depressants.

Due to the documented risk of serious escalation, the official labeling mandates an immediate emergency response. Patients or caregivers must seek immediate medical attention and get emergency help at once if an overdose is suspected or confirmed.

Overdose is classified as potentially life-threatening due to the possibility of respiratory depression and cardiovascular compromise. Management involves general symptomatic and supportive measures, including continuous monitoring of the patient’s respiration, pulse, and blood pressure. While no specific antidote is known, regulatory documents advise that any intervention with agents like flumazenil must be approached with caution due to the potential to induce convulsions. Prescribers are advised to provide the least amount feasible to patients with co-morbid depression to mitigate the risk of intentional overdose.

Therapeutic Uses of Ambien CR

What Ambien CR Treats: Main Uses and Benefits

The extended-release formulation of zolpidem is commonly used to help with adults who have trouble falling asleep or staying asleep. This medication is applied across therapeutic domains involving certain distressing symptoms that interfere with daily functioning.

This supportive therapy is considered relevant for use in conditions characterized by periods of heightened symptoms, such as chronic primary insomnia, and it may also assist when sleep disturbances are associated with other conditions, including general anxiety or depression. The core indications center on addressing both the difficulties with sleep onset and sleep maintenance. The medication supports the reduction of time to sleep onset and helps with maintaining sleep.

The primary therapeutic goal is to help patients experience a reduction in sleep fragmentation, which supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load. This provides supportive relief when symptoms interfere with routine activities, assisting with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Sleep Fragmentation
This medication is applied in situations requiring dual symptomatic support: addressing the initial difficulty of falling asleep and the need for supportive relief from nocturnal awakenings.

Regulatory References

  1. FDA Patient Medication Guide for Ambien CR

Eligibility and Restrictions for Use

Who Can and Cannot Use Ambien CR?

Ambien CR (zolpidem tartrate extended-release) is a prescription medication with strictly defined eligibility and contraindication guidelines based on official regulatory documentation.

Eligible Population

Use is established and allowed only in adults aged 18 years and older. The safety and effectiveness of this medication have not been established in pediatric patients, thus excluding all individuals under the age of 18 from use.

Contraindications (Must Not Use)

Ambien CR is formally contraindicated in several patient groups:

  • Patients with a known hypersensitivity to zolpidem or any of its inactive ingredients, which may manifest as angioedema or anaphylaxis.
  • Individuals who have previously experienced complex sleep behaviors (CSBs), such as sleep-driving or making/eating food while not fully awake, after taking zolpidem.
  • Patients with severe hepatic (liver) impairment, as use may increase the risk of precipitating encephalopathy.

Restrictions and Special Considerations

While not strictly contraindicated, patients with mild to moderate hepatic impairment or those who are elderly or debilitated must be prescribed a lower starting dose due to altered drug metabolism. Use during pregnancy is associated with risks, particularly when taken late in the third trimester. Lactating women may choose to temporarily interrupt breastfeeding for 23 hours after administration to minimize infant exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ambien CR (zolpidem tartrate extended-release) has officially documented interaction patterns primarily categorized as pharmacodynamic (PD) and pharmacokinetic (PK), establishing specific restrictions and requirements for co-administration.

Documented Interaction Classes

The most significant PD interaction is the Additive Central Nervous System (CNS) Depressant Effect that occurs when co-administered with substances like alcohol, opioids, or other sedative-hypnotics. Regulatory documents state that this combination increases the risk of profound sedation, respiratory depression, and complex sleep behaviors. Co-administration with alcohol is explicitly cautioned against due to this synergistic risk.

PK interactions are primarily mediated through the CYP3A4 enzyme system. Substances classified as potent CYP3A4 inhibitors, such as ketoconazole, officially increase zolpidem plasma concentration and exposure (AUC), which may enhance its effects. Conversely, CYP3A4 inducers, such as rifampin or St. John’s Wort, officially reduce zolpidem plasma levels and clearance, risking diminished efficacy. Additionally, ingestion with or immediately after a meal officially decreases the rate and extent of absorption of zolpidem.

Specific population notes indicate that patients with severe hepatic impairment are susceptible to increased zolpidem exposure, and elderly patients are noted to have increased sensitivity to the additive CNS-depressant effects documented in the official regulatory prescribing information.

Mechanism of Action

How Ambien CR Works

Ambien CR (zolpidem) acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABAA) receptor complex within the central nervous system (CNS). This mechanism does not involve direct agonism but rather enhances the effects of the natural inhibitory neurotransmitter, GABA. The binding of zolpidem increases the frequency of chloride channel opening, facilitating a greater influx of chloride ions into the neuron.

This action promotes neuronal hyperpolarization, which reduces overall neuronal excitability. The drug exhibits a focused affinity for GABAA receptors that contain the alpha 1 subunit, which are prevalent in areas of the brain involved in regulating arousal states. This selective engagement intensifies the inhibitory signal within specific neuronal circuits. The effect results in a reduction in signaling within CNS networks associated with arousal, influencing the physiological state in a manner consistent with the initiation and maintenance of sleep.

Dosage and Administration Information

The extended-release formulation of zolpidem tartrate, Ambien CR, is designated strictly for oral administration as a dual-layer tablet. The core usage principle is a once daily regimen, taken immediately before the intended sleep period. This medication is available in two primary strengths: 6.25 mg and 12.5 mg.


Standard Administration and Dosing

The total dose administered should not exceed 12.5 mg in a single nightly dose. Initial doses are determined based on sex. For adult women, the standard initial dose is a single 6.25 mg tablet. For adult men, the initial dose is either 6.25 mg or 12.5 mg once per night. If the lower dose of 6.25 mg is determined to be inadequate, the dose may be adjusted up to the 12.5 mg maximum.


Contextual Usage Constraints

The administration of Ambien CR is subject to two critical timing constraints. First, the medication must only be taken when the user is prepared to commit to a full sleep duration of at least seven to eight hours. Second, the tablet should not be readministered at any point during the same night. Because the tablet features an extended-release design, it must be swallowed whole and should never be divided, crushed, or chewed. Taking the dose with or immediately following a meal may slow the onset of the effect. The drug is intended for short-term use.


Population Adjustments

Specific dose adjustments are applied to certain patient populations. Older adults, along with patients experiencing mild to moderate hepatic impairment, are administered the reduced dose of 6.25 mg once daily immediately before bedtime. Use in patients with severe hepatic impairment is generally avoided.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ambien CR

Evidence for Use in Chronic Primary Insomnia

The core research examining this compound consists primarily of Randomized Controlled Trials (RCTs), a key study design reviewed by regulators. These trials are double-blind and compare the compound against an inactive placebo. Studies were used in research exploring how symptoms change over time, and they were designed to measure outcomes related to sleep onset and sleep maintenance throughout the night.

Research examined outcomes using two main types of measurements. Objective measures used instruments like Polysomnography (PSG) to monitor and record sleep metrics such as the time it took to fall asleep (Sleep Onset Latency, SOL) and the total time spent awake during the night (Wake After Sleep Onset, WASO). Patient-reported outcomes describing perceived discomfort were also used. Research highlights changes measured during the study period across these different metrics.

Evidence in Patients with Co-Occurring Conditions

Studies have explored the use of the compound in patients who experience insomnia alongside other health conditions, specifically focusing on conditions involving periods of heightened symptoms such as mood or anxiety disorders. These trials were designed to examine temporary physiological imbalance in sleep patterns.

Insomnia Associated with Mood Disorders

The research that was studied for this compound in patients with Major Depressive Disorder (MDD) was conducted during periods of increased symptom activity. This research examined the compound as part of a combination treatment, used concomitantly with a standard antidepressant. Findings describe group patterns related to specific sleep outcomes when the compound was evaluated in this adjunctive capacity for up to eight weeks.

Long-Term Research and Maintenance of Outcomes

The longest pivotal trials that regulatory bodies reviewed monitored outcomes over a duration of six months (24 weeks). This research contributed to understanding symptom patterns over an intermediate period. However, there is limited information for long-term outcomes, as research on continuous effects beyond this six-month benchmark is not as extensively established in the primary regulatory filings. Long-term effects are not fully established.

What Remains Uncertain in the Research

Evidence highlights what is known—and what is still uncertain—about this compound. Data for pediatric populations and pregnant or nursing women remain insufficient. Also, research on patients with co-occurring MDD or GAD was conducted as adjunctive therapy, which means the specific effects of the compound on sleep in these groups, independent of the antidepressant, are not isolated.

Key Studies & References

  1. Zolpidem extended-release (Ambien CR): a review of available data on clinical efficacy and safety
  2. FDA Patient Medication Guide for Ambien CR (Zolpidem Tartrate Extended-Release) - DailyMed
  3. Zolpidem: StatPearls [Internet] - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Ambien CR (FAQ)

Q: How long does it typically take for Ambien CR to start working?

Regulatory information indicates that the medication should be taken immediately before bedtime. Taking the dose with or right after a meal may slow down the speed at which the medication is absorbed. This information is often provided to explain the conditions under which the medication is studied.


Q: Is it common to feel groggy or sleepy the morning after taking Ambien CR?

Official safety information classifies next-day somnolence (drowsiness) and dizziness as commonly observed side effects, meaning they were reported in at least 1 in 100 patients during studies. The extended-release formulation is specifically noted to carry a risk of residual effects that can last into the next day.


Q: Can Ambien CR be taken every single night for a long period?

Official regulatory documents indicate that this medication is intended only for short-term use. The risk of developing dependence or misuse may increase the longer the medication is taken. Therefore, official guidelines state the necessity for ongoing re-evaluation by a healthcare provider for any extended treatment.


Q: Do official documents mention tolerance or dependence with Ambien CR use?

Yes, regulatory documents explicitly mention the potential for developing drug dependence, noting that this risk increases with the duration of treatment. Re-evaluating the user’s status is considered necessary when treatment duration is extended beyond the short term.


Q: Can Ambien CR cause rebound insomnia when stopped?

Official safety information notes the potential for rebound insomnia upon abrupt discontinuation of the medication. Rebound insomnia is described as a temporary worsening of sleep difficulties that exceeds the original severity of the problem.


Q: Does taking Ambien CR with food change how it works?

According to official documentation, taking the tablet with or immediately following a meal may decrease the rate and extent of absorption of the active ingredient. This pharmacokinetic change is described as potentially slowing down the onset of the medication’s intended effect.


Q: Why is it important to go to bed immediately after taking Ambien CR?

Official guidelines specify taking the dose only when you are prepared to commit to a full sleep duration of 7 to 8 hours. Official administration information links this timing requirement to the reduced potential risk of complex sleep behaviors, such as sleepwalking or sleep-driving.


Q: Are there known interactions between Ambien CR and common pain relievers?

Official documents explicitly warn that taking the medication with opioids increases the risk of profound sedation and respiratory depression. Interactions with common non-opioid pain relievers (like ibuprofen or acetaminophen) are not formally documented under the same severe risk classifications.


Q: Does Ambien CR interact with commonly prescribed antidepressants?

Yes, official safety information warns that taking Ambien CR concomitantly with certain antidepressants, including tricyclic antidepressants (TCAs), carries an increased risk of CNS depression. Other classes of antidepressants (such as SSRIs) have also been noted in clinical data for potential interactions.


Q: How long does the effect of Ambien CR typically last?

The official administration instructions require that the user be prepared to commit to a full sleep duration of at least seven to eight hours after taking the medication. This guideline is provided because the extended-release formula is designed for effects that last throughout this period.


Q: Are there any specific foods or drinks to avoid when taking Ambien CR?

Official regulatory warnings explicitly caution against taking this medication with alcohol, as the combination significantly increases the risk of severe sedation and respiratory depression. Taking the medication with food, as opposed to without, may also change how it works.


Q: What should I do if I miss a dose of Ambien CR?

Patient instructions typically describe the need to skip a missed dose and wait until the next scheduled dose, due to the requirement for a full night’s sleep (7 to 8 hours). The medication should not be re-administered during the same night.


Q: Why do some people report feeling strange or having vivid dreams on Ambien CR?

Official documents list abnormal dreams and nightmares as uncommon adverse reactions. These symptoms were reported in 0.1% to 1.0% of patients during clinical trials, indicating they are documented, although not common, occurrences.


Q: Do official sources list Ambien CR as being safe for children?

No. Official documents state that the safety and effectiveness of this medication have not been established in pediatric patients. Use is restricted to adults aged 18 years and older.


Q: What is the difference between physical dependence and psychological dependence in the context of Ambien CR?

While regulatory documents warn about the risk of general drug dependence with extended use, they also note that abrupt discontinuation may lead to withdrawal effects such such as muscle cramps, vomiting, and tremors. These physical symptoms are commonly associated with physical dependence.


Q: Can the extended-release formula change how the drug interacts with other medicines?

The extended-release formula provides a more sustained level of the active ingredient in the body compared to the immediate-release form. This sustained exposure is the basis for the warnings regarding potential next-day impairment and the required 7 to 8-hour commitment to sleep.


Q: What is the intended purpose of Ambien CR as described in its regulatory documents?

The medication is formally indicated for the short-term treatment of insomnia in adults. Its specific design targets difficulties with both sleep onset (falling asleep) and/or sleep maintenance (staying asleep), according to official prescribing information.


Q: What are the official guidelines for stopping Ambien CR?

Official guidelines highlight that the risk of withdrawal effects, including rebound insomnia, is a concern upon abrupt discontinuation. Regulatory documents note that treatment duration is intended to be as short as possible and that treatment extension requires re-evaluation of the patient's condition.


Q: Is there a link between Ambien CR and changes in appetite or weight?

Official documents note that changes in appetite have been reported. Anorexia (loss of appetite) is listed as an uncommon adverse reaction, and increased appetite is also listed as a rare side effect in some regulatory data.


Q: Is it official that Ambien CR can cause dizziness or loss of balance?

Yes, dizziness is listed as a common adverse reaction in official documents. Furthermore, gait disturbance (abnormal walking) and falls are listed as rare adverse reactions, and the risk of falls is officially noted to be increased in older adults.


Q: What does the research say about long-term safety of Ambien CR?

Regulatory filings note that the clinical trials supporting the efficacy of Ambien CR were monitored for up to 24 weeks. However, the medication is only indicated for short-term use, and official documents recommend ongoing patient re-evaluation if the treatment duration is extended.


Q: Is the medication designed for people who have trouble falling asleep, staying asleep, or both?

The medication is indicated for the treatment of insomnia characterized by difficulties with sleep onset (falling asleep) and/or sleep maintenance (staying asleep).


Q: Can people with respiratory problems or sleep apnea take Ambien CR?

Official warnings state that taking this medication with other CNS depressants may increase the risk of respiratory depression (slowed or shallow breathing). The full prescribing information details that the use of sedative-hypnotics in patients with respiratory insufficiency or sleep apnea is a specific consideration that must be addressed.

How should Ambien CR be stored and disposed of?

Storage and Disposal of Ambien CR (Zolpidem Tartrate Extended-Release Tablets)

Ambien CR must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and maintained with the lid tightly closed to protect integrity. Storage requires placing the tablets out of the reach of children.

Disposal Requirements

Official disposal instructions advise using a drug take-back program when available. If a program is unavailable, the whole, uncrushed tablets must be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash. Do not flush this medication down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ambien CR found in:

A-Z Index: